Abstract
ABSTRACTThe malaria parasite Plasmodium falciparum is responsible for over 200 million infections and 400,000 deaths per year. At multiple stages during its complex life cycle, P. falciparum expresses several essential proteins tethered to its surface by glycosylphosphatidylinositol (GPI) anchors, which are critical for biological processes such as parasite egress and reinvasion of host red blood cells. Targeting this pathway therapeutically has the potential to broadly impact parasite development across several life stages. Here, we characterize an upstream component of GPI anchor biosynthesis, the putative phosphomannomutase (EC 5.4.2.8) of the parasites, HAD5 (PF3D7_1017400). We confirm the phosphomannomutase and phosphoglucomutase activity of purified recombinant HAD5. By regulating expression of HAD5 in transgenic parasites, we demonstrate that HAD5 is required for malaria parasite egress and erythrocyte reinvasion. Finally, we determine the three-dimensional crystal structure of HAD5 and identify a substrate analog that specifically inhibits HAD5, compared to orthologous human phosphomannomutases. These findings demonstrate that the GPI anchor biosynthesis pathway is exceptionally sensitive to inhibition, and that HAD5 has potential as a multi-stage antimalarial target.
Publisher
Cold Spring Harbor Laboratory
Reference107 articles.
1. World Health Organization (2020) World Malaria Report 2020: 20 years of global progress and challenges, Geneva, [online] https://www.who.int/publications/i/item/9789240015791 (Accessed May 14, 2021)
2. Drug resistance in Plasmodium
3. Malaria - Update on Antimalarial Resistance and Treatment Approaches;Pediatr. Infect. Dis. J,2018
4. Biology of Malaria Transmission
5. A Research Agenda to Underpin Malaria Eradication